Back to Search
Start Over
Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands
- Source :
- Clinical Lymphoma Myeloma & Leukemia, 18(1), 52-57. CIG Media Group, L.P., Clinical lymphoma, myeloma & leukemia, 18(1), 52-57. Cancer Media Group, Clinical Lymphoma Myeloma and Leukemia, 18(1), 52-57. Cancer Media Group
- Publication Year :
- 2017
-
Abstract
- Considerable progress has been made in treatment of patients with CLL, and new potent drugs have become available. Therefore the Dutch CLL guidelines were revised. Efficacy, quality of life and socio-economic impact were taken into account. This has led to guidelines with chemo-immunotherapy still as the cornerstone of CLL treatment and with novel targeted drugs for specific risk-groups. Introduction: In recent years, considerable progress has been made in the treatment of patients with chronic lymphocytic leukemia (CLL), and new potent drugs have become available. Therefore, the CLL working party revised the Dutch guidelines. Not only efficacy but also quality of life and socio-economic impact were taken into account in the formulation of treatment recommendations. Materials and Methods: The working party discussed a set of questions regarding diagnostic tests and treatment and wrote the draft guideline. This was evidence-based whenever possible, but in cases of low evidence, an expert-based recommendation was formulated with input of the entire working party. The draft guideline was sent to all hematologists in the Netherlands for comment and was subsequently approved. Results: Recommendations were formulated on diagnostic tests and work-up before treatment. Also, recommendations were made for treatment with fludarabine-cyclophosphamide-rituximab, bendamustine-rituximab, chlorambucil with anti-CD20 antibody, ibrutinib, idelalisib-rituximab, venetoclax, and allogeneic stem cell transplantation. Conclusion: In the revised Dutch CLL guidelines, chemo-immunotherapy is still the cornerstone of CLL treatment with novel targeted drugs for specific risk groups. (C) 2017 Elsevier Inc. All rights reserved.
- Subjects :
- Bendamustine
Cancer Research
medicine.medical_specialty
Chronic lymphocytic leukemia
Guidelines as Topic
PLUS CHLORAMBUCIL
Chemo-immunotherapy
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
immune system diseases
hemic and lymphatic diseases
CYCLOPHOSPHAMIDE
medicine
Humans
RITUXIMAB
030212 general & internal medicine
IBRUTINIB
Intensive care medicine
Reimbursement
Netherlands
PHASE-3 TRIAL
Chlorambucil
business.industry
Venetoclax
PREVIOUSLY UNTREATED PATIENTS
STEM-CELL TRANSPLANTATION
Hematology
Guideline
OPEN-LABEL
medicine.disease
Leukemia, Lymphocytic, Chronic, B-Cell
Transplantation
1ST-LINE TREATMENT
Oncology
chemistry
Kinase inhibitors
Small lymphocytic lymphoma
030220 oncology & carcinogenesis
Ibrutinib
Immunology
BENDAMUSTINE
Health economics
business
medicine.drug
Subjects
Details
- ISSN :
- 21522669 and 21522650
- Volume :
- 18
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Clinical lymphoma, myelomaleukemia
- Accession number :
- edsair.doi.dedup.....1e9ddb866cbdf0da6fbd9e8f38370488